History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti arrhythmic medication.
Current cardiac arrhythmic condition requiring concurrent use of anti-arrhythmic drug; rate controlled atrial fibrillation is allows
Current cardiac arrhythmia requiring concurrent use of anti-arrhythmic drugs
Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
Patients with cardiac ventricular arrhythmias requiring anti-arrhythmic therapy are not eligible
History of cardiac ventricular arrhythmias requiring anti-arrhythmic therapy within past 3 months
Patients with history of atrial arrhythmia (requiring any anti-arrhythmic therapy) or patients with any history of ventricular arrhythmia are excluded
Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
Cardiac arrhythmias requiring anti-arrhythmic medications (Subject with rate controlled atrial fibrillation for > 1 month prior to first dose of study drugs are eligible)
> Class II Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
Patients on anti-arrhythmic drugs
Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti-arrhythmic medication.
Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
Anti-arrhythmic and heart rate lowering drugs.
Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
Significant cardiovascular disease including:\r\n* Active, clinically symptomatic left ventricular failure\r\n* Uncontrolled symptomatic hypertension that cannot be controlled with anti-hypertensive agents\r\n* Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug\r\n* History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) \r\n* Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)  \r\n* Coronary or peripheral artery bypass graft within 6 months of screening
Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
Need for anti-arrhythmic therapy for a ventricular arrhythmias
Patients with cardiac arrhythmias must not be receiving anti-arrhythmic medication at time of study entry (or while on study).
High-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade atrioventricular [AV]-block, supra-ventricular arrhythmias which are not adequately rate-controlled) that require current treatment with the following anti-arrhythmic drugs: flecainide, moricizine or propafenone
Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
Patients on anti-arrhythmic drugs